Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change
- PMID: 8726546
- DOI: 10.1097/00002826-199619030-00009
Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change
Abstract
We investigated the effect of carbamazepine (CBZ) cotreatment with haloperidol (HP) on cardiac change in Japanese psychiatric patients without heart disease. Of 21 patients cotreated with CBZ, 11 showed lengthening of QT interval corrected for heart rate (QTc) (> 440, mean percentage change, 29), of whom two patients developed congestive heart failure because of left ventricular dysfunction. Especially in these two patients, plasma HP levels were significantly higher than speculated from the correlations. It is possible to speculate that, especially on CBZ cotreatment, significantly higher HP plasma level with QTc prolongation may herald heart failure.
Comment in
-
Response to Iwashashi: "significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change".Clin Neuropharmacol. 1997 Apr;20(2):179. Clin Neuropharmacol. 1997. PMID: 9099473 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous